DK0782709T3 - Detektering af cancer - Google Patents
Detektering af cancerInfo
- Publication number
- DK0782709T3 DK0782709T3 DK95940906.1T DK95940906T DK0782709T3 DK 0782709 T3 DK0782709 T3 DK 0782709T3 DK 95940906 T DK95940906 T DK 95940906T DK 0782709 T3 DK0782709 T3 DK 0782709T3
- Authority
- DK
- Denmark
- Prior art keywords
- patient
- afp
- cancer cells
- introducing
- labeled
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57476—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncofetal proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/92—Detection of biochemical
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30814194A | 1994-09-19 | 1994-09-19 | |
PCT/IB1995/000902 WO1996009551A1 (en) | 1994-09-19 | 1995-09-18 | Detection and treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0782709T3 true DK0782709T3 (da) | 2010-03-29 |
Family
ID=23192727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK95940906.1T DK0782709T3 (da) | 1994-09-19 | 1995-09-18 | Detektering af cancer |
Country Status (15)
Country | Link |
---|---|
US (1) | US6514685B1 (da) |
EP (3) | EP0782709B1 (da) |
KR (1) | KR970706498A (da) |
CN (2) | CN100472213C (da) |
AT (1) | ATE449342T1 (da) |
AU (1) | AU714966B2 (da) |
BR (1) | BR9508959A (da) |
CA (1) | CA2197490A1 (da) |
DE (1) | DE69536019D1 (da) |
DK (1) | DK0782709T3 (da) |
ES (1) | ES2336976T3 (da) |
FI (1) | FI121353B (da) |
NO (1) | NO323754B1 (da) |
RU (1) | RU2161042C2 (da) |
WO (1) | WO1996009551A1 (da) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115399B2 (en) * | 2001-07-31 | 2006-10-03 | Allergan, Inc. | Pinna reflex assay |
AU2003216048A1 (en) * | 2002-01-10 | 2003-07-30 | David Kleinfeld | Iterative optical based histology |
AU2004207233C1 (en) * | 2003-01-24 | 2008-04-24 | Agensys, Inc. | Nucleic acids and corresponding proteins entitled 254P1D6B useful in treatment and detection of cancer |
CN100360684C (zh) * | 2005-02-01 | 2008-01-09 | 合肥中科大生物技术有限公司 | 甲胎蛋白(AFP)mRNA荧光定量RT-PCR检测试剂盒 |
US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
CN101730708B (zh) | 2007-03-28 | 2013-09-18 | 哈佛大学校长及研究员协会 | 缝合多肽 |
CA2733223C (en) | 2008-08-05 | 2018-02-27 | Toray Industries, Inc. | Pharmaceutical composition comprising anti-caprin-1 antibody for treatment and prevention of cancers |
MX2011001445A (es) | 2008-08-05 | 2011-04-05 | Toray Industries | Metodo para detectar cancer. |
US8968210B2 (en) * | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
CA2774973A1 (en) | 2009-09-22 | 2011-03-31 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
US20120270238A1 (en) * | 2009-10-22 | 2012-10-25 | Moro Ricardo J | Peptides That Bind the Alpha-Fetoprotein (AFP) Receptor and Uses Thereof |
RU2624029C2 (ru) * | 2010-02-04 | 2017-06-30 | Торэй Индастриз, Инк. | Лекарственный препарат для лечения и/или профилактики рака |
EP2889295A1 (en) | 2010-08-12 | 2015-07-01 | New York University | Oligooxopiperazines and methods of making and using them |
CA2807685C (en) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | P53 derived peptidomimetic macrocycle |
WO2013018885A1 (ja) | 2011-08-04 | 2013-02-07 | 東レ株式会社 | 膵臓癌の検出方法 |
US9096684B2 (en) | 2011-10-18 | 2015-08-04 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
JP6450192B2 (ja) | 2012-02-15 | 2019-01-09 | エイルロン セラピューティクス,インコーポレイテッド | トリアゾール架橋した、およびチオエーテル架橋したペプチドミメティック大環状化合物 |
WO2013123266A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
EP2814821B1 (en) | 2012-02-16 | 2018-04-25 | New York University | Control of hypoxia-inducible gene expression with oligooxopiperazine nonpeptidic helix mimetics |
RU2646466C2 (ru) | 2012-07-19 | 2018-03-05 | Торэй Индастриз, Инк. | Метод детекции рака |
US9604919B2 (en) | 2012-11-01 | 2017-03-28 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
CA2918989C (en) | 2013-08-09 | 2021-11-02 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
SG11201702175YA (en) | 2014-09-24 | 2017-04-27 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and formulations thereof |
AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
BR112017019738A2 (pt) | 2015-03-20 | 2018-05-29 | Aileron Therapeutics Inc | macrociclos peptidomiméticos e usos dos mesmos |
WO2017004548A1 (en) | 2015-07-01 | 2017-01-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
EP3371211A4 (en) | 2015-11-04 | 2019-08-21 | Icahn School of Medicine at Mount Sinai | METHOD FOR THE TREATMENT OF TUMORS AND CANCER AND IDENTIFICATION OF CANDIDATE PATIENTS FOR SUCH TREATMENT |
WO2017189730A1 (en) | 2016-04-26 | 2017-11-02 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
CN106290876B (zh) * | 2016-08-11 | 2018-06-29 | 湖南新大陆生物技术有限公司 | 一种肿瘤细胞检测方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2701710B1 (fr) * | 1993-02-18 | 1995-04-21 | Intromed Ltd | Conjugués protéiques, compositions les contenant et leurs applications en tant que médicament et réactif de diagnostic. |
-
1995
- 1995-09-18 EP EP95940906A patent/EP0782709B1/en not_active Expired - Lifetime
- 1995-09-18 ES ES95940906T patent/ES2336976T3/es not_active Expired - Lifetime
- 1995-09-18 RU RU97106059/14A patent/RU2161042C2/ru not_active IP Right Cessation
- 1995-09-18 DK DK95940906.1T patent/DK0782709T3/da active
- 1995-09-18 AU AU37648/95A patent/AU714966B2/en not_active Ceased
- 1995-09-18 CN CNB200310104769XA patent/CN100472213C/zh not_active Expired - Fee Related
- 1995-09-18 CA CA002197490A patent/CA2197490A1/en not_active Abandoned
- 1995-09-18 EP EP08002689A patent/EP1955714A1/en not_active Withdrawn
- 1995-09-18 WO PCT/IB1995/000902 patent/WO1996009551A1/en not_active Application Discontinuation
- 1995-09-18 CN CN95195125A patent/CN1132012C/zh not_active Expired - Fee Related
- 1995-09-18 BR BR9508959A patent/BR9508959A/pt not_active Application Discontinuation
- 1995-09-18 DE DE69536019T patent/DE69536019D1/de not_active Expired - Lifetime
- 1995-09-18 EP EP08002690A patent/EP1956374A1/en not_active Withdrawn
- 1995-09-18 KR KR1019970701775A patent/KR970706498A/ko not_active Application Discontinuation
- 1995-09-18 AT AT95940906T patent/ATE449342T1/de not_active IP Right Cessation
-
1997
- 1997-03-10 FI FI970990A patent/FI121353B/fi not_active IP Right Cessation
- 1997-03-18 NO NO19971256A patent/NO323754B1/no not_active IP Right Cessation
- 1997-08-15 US US08/920,654 patent/US6514685B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
FI121353B (fi) | 2010-10-15 |
ATE449342T1 (de) | 2009-12-15 |
RU2161042C2 (ru) | 2000-12-27 |
AU3764895A (en) | 1996-04-09 |
AU714966B2 (en) | 2000-01-13 |
CA2197490A1 (en) | 1996-03-28 |
EP1955714A1 (en) | 2008-08-13 |
CN1169778A (zh) | 1998-01-07 |
US6514685B1 (en) | 2003-02-04 |
BR9508959A (pt) | 1997-12-30 |
CN1132012C (zh) | 2003-12-24 |
CN100472213C (zh) | 2009-03-25 |
EP0782709B1 (en) | 2009-11-18 |
WO1996009551A1 (en) | 1996-03-28 |
NO971256L (no) | 1997-03-18 |
NO971256D0 (no) | 1997-03-18 |
ES2336976T3 (es) | 2010-04-19 |
KR970706498A (ko) | 1997-11-03 |
CN1502994A (zh) | 2004-06-09 |
DE69536019D1 (de) | 2009-12-31 |
FI970990A (fi) | 1997-03-10 |
EP1956374A1 (en) | 2008-08-13 |
EP0782709A1 (en) | 1997-07-09 |
NO323754B1 (no) | 2007-07-02 |
FI970990A0 (fi) | 1997-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0782709T3 (da) | Detektering af cancer | |
DE69910007D1 (de) | Vorrichtung zum vorhersagen von physiologischen messwerten | |
ATE246361T1 (de) | Verfahren zur bestimmung von ige | |
NO904001D0 (no) | Fremgangsmaate og anordning for amperometrisk diagnoseanalyse. | |
ATE159982T1 (de) | Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung | |
ATE297950T1 (de) | Testverfahren und reagenzien zur quantifizierung von hbnp | |
ES2125272T3 (es) | Metodo de biosensor de sonda genica. | |
ATE312946T1 (de) | Verfahren und vorrichtung zur bestimmung der gewebespezifität von freier dna in körperflüssigkeiten | |
DE68923800D1 (de) | Vorrichtung und verfahren zur bestimmung eines analyten in einer flüssigen probe mittels folgereaktionen. | |
ATE200151T1 (de) | Analytische testvorrichtung einschliesslich negativ- und positivkontrolle | |
RU97106059A (ru) | Обнаружение и лечение рака | |
DE3584796D1 (de) | Verfahren und vorrichtung zur durchfuehrung analytischer bestimmungen. | |
ES2121358T3 (es) | Anticuerpos monoclonales humanizados contra interleuquina-4 humana. | |
DE3856004T2 (de) | Verwendung von monoclonalen rezeptoren gegen oncoproteinen zur überwachung von krebstherapie | |
DE69928250D1 (de) | Analytisches verfahren unter verwendung von multipelviren-markierung | |
HUP9800225A2 (hu) | Eljárás és vegyületek analitok meghatározására remanenciaméréssel és ezek alkalmazásai | |
EP1159614A4 (en) | DIAGNOSTIC METHOD FOR ASTHMA | |
ATE210294T1 (de) | Immunoassay vorrichtung und testverfahren zu seiner verwendung | |
ATE208040T1 (de) | Immunoassay-reagenzien, testsätze und verfahren | |
DE60143227D1 (de) | Vorrichtung und verfahren zur bestimmung des eintretens und vorhandenseins septischer bedingungen | |
DE59913949D1 (de) | Humane monoklonale antikörper gegen inselzellantigen ia-2 | |
ATE195183T1 (de) | Methode zur bestimmung einer substanz | |
FR2848474B1 (fr) | Reacteur chimique, et procede de determination de parametres de fixation d'une espece chimique sur un materiau solide, mettant en oeuvre ce reacteur | |
CU22729A1 (es) | Procedimiento para la obtención de sueros hiperinmunes antiespecies para la identificación de tejidos biológicos |